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Abstract
Background: Since the cloning in 1990 of cDNA corresponding to mRNA transcribed at the
blood-group ABO locus, polymorphisms due to ethnic and/or phenotypic variations have been
reported. Some subgroups have been explained at the molecular level, but unresolved samples are
frequently encountered in the reference laboratory.
Results: ABO blood grouping discrepancies were investigated serologically and by ABO genotyping
[duplex polymerase-chain-reaction (PCR) – restriction-fragment-length-polymorphism (RFLP) and
PCR – allele-specific-primer (ASP) across intron 6] and DNA sequencing of the ABO gene and its
proposed regulatory elements. Blood samples from five individuals living in Portugal, Switzerland,
Sweden and the USA were analysed. These individuals were confirmed to be of Black ethnic origin
and had the unusual AweakB phenotype but appeared to have the A2B genotype without previously
reported mutations associated with weak A or B expression. Sequencing of this A allele (having
467C>T and 1061delC associated with the common A2 [A201] allele) revealed three mutations
regularly encountered in the O1v [O02] allele: 106C>T (Val36Phe), 188G>A (Arg63His), 220C>T
(Pro74Ser) in exons 3, 4 and 5, respectively. The additional presence of 46G>A (Ala16Thr) was
noted, whilst 189C>T that normally accompanies 188G>A in O1v was missing, as were all O1v-
related mutations in exons 6 and 7 (261delG, 297A>G, 646T>A, 681G>A, 771C>T and 829G>A).
On screening other samples, 46G>A was absent, but two new O alleles were found, a Jordanian O1
and an African O1v allele having 188G>A but lacking 189C>T. Sequencing of introns 2, 3, 4 and 5 in
common alleles (A1 [A101], A2, B [B101], O1, O1vand O2 [O03]) revealed 7, 12, 17 and 8 polymorphic
positions, respectively, suggesting that alleles could be defined by intronic sequences. These
polymorphic sites allowed definition of a breakpoint in intron 5 where the O1v-related sequence
was fused with A2 to form the new hybrid. Intron 6 has previously been sequenced. Four new
mutations were detected in the hybrid allele and these were subsequently also found in intron 6 of
A2 alleles in other Black African samples.
Published: 17 November 2003
BMC Genetics 2003, 4:17
Received: 05 September 2003
Accepted: 17 November 2003
This article is available from: http://www.biomedcentral.com/1471-2156/4/17
© 2003 Hosseini-Maaf et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted 
in all media for any purpose, provided this notice is preserved along with the article's original URL.BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/17
Page 2 of 11
(page number not for citation purposes)
Conclusions: A novel O1v-A2 hybrid was defined by ABO exon/intron analysis in five unrelated
individuals of African descent with the AweakB blood group phenotype.
Background
The ABO blood group system is the most clinically signif-
icant system in transfusion and transplantation medicine.
The A and B genes are co-dominant, so individuals can be
phenotyped as A, B, AB or O. A common dimorphism in
some populations leads to the division of blood group A
into A1 and A2, the latter showing weaker antigenicity. On
occasion, A2 activity is weakened further when competi-
tion due to a co-dominant B  gene occurs (A2B
phenotype).
ABO allele nomenclature poses significant problems that
are still under consideration by the International Society
of Blood Transfusion (ISBT). In the absence of an offi-
cially agreed terminology, alleles are referred to here by
their serological activity and an alternative allele name1 is
given in square brackets.
The ABO gene contains seven exons and a 1062 base pair
(bp) sequence codes for a glycosyltransferase, of which
the A1 [A101] allele (usually described as the consensus
allele) product adds a monosaccharide (N-acetyl-α-D-
galactosamine) to a specific acceptor glycoconjugate. The
B [B101] allele produces a similar protein, differing only
in four amino acids, but these changes result in a modi-
fied enzyme specificity [2]. The same acceptor glycoconju-
gate is utilised, but the B-specific monosaccharide, α-D-
galactose, is added (for a review, see [3]). The coding
region of the A2 [A201] allele differs from A1 by a seem-
ingly innocuous 467C>T (Pro156Leu) substitution and a
1061delC that causes a frame-shift and extends the read-
ing frame by 64 nucleotides [4]. Many other mutations
have been described [5] that weaken these activities and
result in weak A or B subgroups. Totally inactivating muta-
tions result in the blood group O phenotype, the most
common of which is a deletion at nucleotide (nt.) 261
(261delG) in exon 6 that results in a frame-shift and pre-
mature termination of translation [2]. Two major alleles
of this type exist. The first allele (O1 [O01]) differs from
the consensus A [A101] allele in all seven exons by only
this mutation. The second allele (O1v [O02]) [6,7] has
nine further mutations spread across exons 3–7 in addi-
tion to 261delG and an additional 13 mutations have
been found amongst the 1052 nucleotides in intron 6
[8,9].
Other alleles have been described that are predicted to
lead to amino acid substitutions or frame-shifts [5], or
alternative splicing [10,11] and a dimorphic enhancer
region has been reported [12-14]. Several alleles at the
ABO locus appear to arise by crossing over between two
dissimilar alleles. First described in 1996 [15], a B allele
was continued as an O1v allele from downstream of the
middle of the last and largest exon (exon 7). The B-
enzyme-determining mutations occur after the cross-over
point and the O1v sequence after this point only differs
from the consensus (A1) sequence by two point muta-
tions, of which only one would lead to an amino acid
change (Val277Met). This change presumably weakened
the A enzyme activity, as the resulting phenotype was A2,
albeit from a B-O1v hybrid allele [A204]. Other examples
on the same theme include several Ax alleles based on the
5'-ends of A or B alleles in combination with the 3'-end of
the O1v allele [9,16]. However, many of the hybrid alleles
described so far are hybrids of O1 and O1v, have 261delG,
and hence are O (i.e. inactive) alleles [17].
We describe here a new hybrid A  allele having O1v-A2
allele characteristics in five individuals of AweakB pheno-
type from different parts of the world, but having a com-
mon ethnic background. This is the first allele described in
which the effect on enzyme activity of the mutations in
the O1v allele prior to exon 6 can be shown.
Results
Blood group serology
The five individuals from Portugal (origin: Guinea Bis-
sau), Sweden (n = 2, origins: Senegal and Zimbabwe),
Switzerland (origin: the Dominican Republic), and the
USA were all Black and of African or Afro-American
descent. On routine typing they were found to express the
A antigen weakly on their red blood cells (RBC) whilst the
B antigen was expressed normally. Fresh blood samples
from all five subjects were subjected to an extended sero-
logical analysis at the referring transfusion centres. Three
of the samples were analysed with a panel of commer-
cially available polyclonal and monoclonal anti-A rea-
gents (described previously in [18]) for further
characterisation of the weak A phenotype. One mono-
clonal reagent (Seraclone) agglutinated the RBC almost
completely (3+ reaction with few unagglutinated cells)
but the other reagents gave mixed field reactions (macro-
scopic reading ranging from negative to 1+/2+). All reac-
tions were also read microscopically and weak
agglutination with mixed field was verified also in the rea-
gents yielding macroscopically negative readings. Adsorp-
tion of red cells with anti-A and subsequent elution
yielded an eluate containing anti-A (only performed in
one case). Anti-A1 was present in serum from all subjects
but one also had a weak anti-A reactive only afterBMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/17
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incubation at 4°C. Saliva testing was not performed due
to lack of saliva samples and/or non-secretor status as
judged by Lewis blood group phenotyping.
Blood samples from the parents of the Portuguese indi-
vidual were also investigated. Whilst the father had the
common B phenotype, the phenotype of the mother was
Aweak but with a strength of reactions suggesting an inter-
mediate form of A antigen expression, weaker than A2 but
stronger than the one observed in the AweakB cases studied
here.
Blood group genotyping
All samples were found on initial genotype screening [19]
to have the A2B genotype and lacked the majority of pre-
viously reported mutations associated with weak A or B
expression [16,20]. Further analysis by A2-specific PCR-
ASP [18] established the presence of the 1061delC muta-
tion [4] and B-specific PCR-ASP [16] indicated the pres-
ence of a normal B allele [21]. In addition, enhancer mini-
satellite PCR analysis indicated that four of these samples
were homozygous for four 43 bp-repeats in the CBF-NF/
Y-binding domain approximately 4 kbp upstream from
the translation start codon, as expected [13]. Interestingly,
the individual originating from the Dominican Republic
was heterozygous for one and four repeats, thus deviating
from the rule [13].
A  BstUI-based PCR-RFLP test [7] results in cleavage
between 188C and 189G in exon 4 of all known alleles
except O1v (and some minor variants of O1 and O1v [5]),
which has two mutations at these positions (188G>A and
189C>T). The indication that these five individuals
already genotyped as A2B were also heterozygous for an
O1v allele-specific mutation led us to sequence exons 1–7
to investigate the reason for this anomaly.
Based on information obtained about the geographic and
ethnic origin of the individuals with the anomalous A
allele, we also performed genomic typing of the FY and
RHD blood group loci according to published methods
[22,23]. The silent Fy allele (based on the Fyb sequence
with a disrupted GATA-1-binding motif in the promoter
region [24]) commonly found in individuals of Black eth-
nic origin but not in Caucasians was detected in the
homozygous or heterozygous state in all five cases whilst
the  RHD  pseudogene [23] exclusively found in some
Blacks was detected in the Portuguese sample only.
DNA was also isolated from blood from the parents of the
Portuguese AweakB individual. The mother was genotyped
as A2O1v and the father as BO1. Further investigation of the
mother's A2-like allele showed the same hybrid allele as
her son and the other four index cases, as expected.
ABO exon sequences
The complete coding region (all seven exons, comprising
1128 bp) of the A2  allele was sequenced in all five
samples.
The nucleotide sequence in exons 6 and 7 was identical to
the non-Asian A1 consensus allele except for the character-
istic mutations (467C>T and 1061delC in exon 7) found
in the common A2 allele.
The sequences in exons 1–5 were similar to the consensus
allele, except for 106G>T (exon 3), 188G>A (exon 4) and
220C>T (exon 5), all consistent with the presence of an
O1v  allele. Surprisingly, the O1v-specific mutation,
189C>T, was absent, whereas a hitherto undescribed
mutation in exon 2 (46G>A) was found in all five sam-
ples. As opposed to the situation in O1v, the effect of these
missense mutations can be seen in the translated trans-
ferase, as the O1/O1v-specific 261delG mutation is not
present in this allele. The amino acids predicted to occur
as well as their relative locations in the translated protein
are shown in Figure 1.
A possible hybrid allele breakpoint was suspected some-
where between the end of exon 5 and the beginning of
exon 6. We therefore sequenced the intervening intron 5
(see below) in an attempt to localise the cross-over region.
None of the more than 100 samples screened by PCR-ASP
(i.e. at least 200 alleles, comprising over 50 O1 and O1v
alleles and at least 10 A1, A2, B, O2 and O hybrid alleles, as
well as several weak A alleles) had the new mutation,
46G>A (Ala16Thr). Amongst all these samples one O1
allele from a Jordanian individual was found to have the
O1v-characteristic 188G>A (Arg63His) mutation. One O1v
allele from an African individual lacked the O1v-character-
istic 189C>T (silent) mutation.
ABO intron sequences
Intron 5
Intron 5 from a number of individuals with the common
alleles, A1 (two homozygotes), A2 (two homozygotes), B
(one homozygote, one heterozygote), O1 (two homozy-
gotes), O1v (two homozygotes),O2 [O03] (three heterozy-
gotes) and the new suspected hybrid alleles was
sequenced. Three A2 and three O1v alleles from Black Afri-
can donors were also sequenced for comparison. Eight
polymorphic nucleotide positions were found in the 554
bp sequence and these are shown in Table 1. Intron 5
sequences in the Black African samples were identical to
the respective alleles of the other (Caucasian) control
material. The sequence in the new allele was consistent
with a crossover between an O1v and an A2 allele after nt.
103insCCC but before 306C in intron 5. This is shown
schematically in Figure 2.BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/17
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Introns 2, 3 and 4
Since the new allele has a novel mutation in exon 2
(46G>A) and an unexpected lack of the O1v-specific muta-
tion in exon 4 (189C>T), other introns in the A2-like allele
of the five AweakB samples were also sequenced and all
gave identical results. Samples from the same 13 Cauca-
sian and three Black individuals examined for intron 5
above were also analysed (Table 1). Intron 1 was not
examined due to its size (approx. 13,000 bp). We found
7, 12 and 17 polymorphic sites (point mutations, dele-
tions and insertions) in introns 2, 3 and 4, respectively, in
the common alleles (Table 1).
The intron 2–4 sequences of the novel allele were identi-
cal to the O1v alleles sequenced except for three adjacent
mutations in intron 3. The first, 205T>C, caused a rever-
sion to the consensus from O1v-specific, whereas 354G>A
and 399G>A were mutations not previously encountered
in any allele. Intron 3 in the O1v alleles from the control
Depiction of the relative locations of amino acid substitutions caused by the novel allele Figure 1
Depiction of the relative locations of amino acid substitutions caused by the novel allele. A schematic representation of the A 
transferase resulting from transcription and translation of the novel allele is shown on the left side whilst a computed 3D-
model on black background is displayed on the right side. In the former, all amino acid substitutions resulting from the four 
missense mutations in the O1v-A2 hybrid are shown as coloured circles highlighted by dotted arrows. In the latter, only two of 
the mutated positions could be displayed in the model since the two N-terminal substitutions were not included in the 
expressed soluble portion of the crystallized A transferase [32] on which the template structure (molecular coordinate file 
1LZ0 in the NCBI structure database) was based. The 3D surface model was created with the DeepView Swiss Pdb Viewer 
version 3.7, an interactive molecular graphics programme for viewing and analyzing protein structure (http://www.expasy.org/
spdbv and [33]) using the molecular surface mode and the 3D rendering display option. No effort was made to calculate the 
possible structural alterations caused by the amino acid changes. The original sequence expressed for the crystallographic 
study [32] was used for the analysis. Residue positions 63 and 74 are highlighted in red and green, respectively, to show their 
relative locations in the model. In addition, the DXD motif (present in almost all glycosyltransferases, here as DVD capable of 
binding the UDP part of the nucleotide-sugar substrate) is shown in blue in order to highlight the catalytic cleft. The different 
regions of the glycosyltransferase are shown according to Paulson and Colley [34] and the transmembrane domain (amino 
acids 17–37) is based on the hydrophobicity plot and amino acid composition originally reported by Yamamoto et al. [35]. The 
black X represents the approximate location of a proteolytic cleavage site for generation of the soluble glycosyltransferase 
found in body fluids.
Globular
enzymatically
active domain
with DVD motif
Stem region
Transmembranous
domain (a.a. 17-37)
Cytoplasmic tail
Pro74Ser
Arg63His
Val36Phe Phe
Ala16Thr ThrBMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/17
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donors of African origin was sequenced and in each case was identical to Caucasian O1v alleles.
Table 1: Polymorphic nucleotide positions in introns 2–5 of the ABO gene.
Intron 2 (724 bp) nt. position
Allele 126 209 362 369 396 437 539
dbSNP rs 20738
28
20738
27
68728
9
687621 20738
26
A1 AC C C TC C
A2 AC C C TC C
B AC C C TC C
O1 AC TGC T A
O2 AA C/T* TGC T A
O1v AC C C CTC
new 
hybrid
AC C C CTC
Intron 3 (1451 bp) nt. position
Allele 205 354 399 479 525 575 969 1063 1095 1096 1170 1244 1278 1357
dbSNP rs 493211 81767
01
57962
2
57948
3
8176702 57525
9
57434
7
81767
04
61342
3
55132
2
62460
1
A1 C GGCA C TA C ACCTC
A2 CG G C ACT A C A T CTC
B C GGCA C TA C ACCTC
O1 CG G C AT TA C ACCTC
O2 CG G C ACT A del del CCTC
O1v T GG TT C CGCA C TCT
new 
hybrid
C AA T TC CGCA C TCT
Intron 4 (1686 bp) nt. position
Allele 28 73 102 114 163 215 216 346 375 738 1092 1176 1467 1496 1511 1623 1678
dbSNP rs 784814
5
615120
3
81767
07
62559
3
81767
08
547495 62603
5
62679
2
63875
6
51741
4
51470
8
64194
3
64195
9
8176
712
4962
040
A1 GC C C GAA T C T C C G T T C T
A2 GC C C GAA T C T C C G T T C T
B GC C C GAA T C T C C G T T C T
O1 GC C / A C G A AT C TCCGTT C C
O2 GC C C GAA T T T T C AGG CT
O1v C ** C TA G CG C G C TAGG CC T
new 
hybrid
C ** C TA G CG C G C TAGG CC T
Intron 5 (554 bp) nt. position
Allele 91 103 266 306 336 450 527 530
dbSNP rs 817671
3
81767
14
81767
15
8176717 81767
18
A1 T C GCG C GA
A2 T C GCG C GA
B TC G C G C G A /G
O1 TC G C A CG A
O2 C CCCC A CG C GA
O1v TC CCC G T G AA A
new 
hybrid
TC CCC GCG C GA
* C/T etc. indicates dimorphism at this position in the same allele from different individuals. ** Insertion of GTGTGGACAGAAG between nt. 72C 
and 73C of the consensus (A1 [A101]) sequence in intron 4. Deviations from the consensus sequence are highlighted (bold italics).BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/17
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Intron 6
Allele-specific variations in intron 6 have already been
described [8,9]. Four new mutations were found in the
new hybrid allele when compared to the A  consensus
sequence (277A>G, 286C>T, 911G>T and 952A>G).
However, intron 6 in three normal A2 alleles from Black
Africans with the common A2 phenotype also had these
mutations.
Discussion
Detailed analysis of the alleles at the blood group ABO
locus is shedding light on the effect of polymorphism in
different regions of the translated products, the blood
group A and B glycosyltransferases, and ultimately the
clinically important ABO phenotype of red cells. Factors
with the potential to influence the glycosyltransferase
activities include base insertions, deletions and substitu-
tions mainly in exons 6 and 7 (for review see [5,25]),
hybrid alleles [17], splice-site mutations [10,11], varia-
tions in enhancer activity [12-14], promoter methylation
[26], promoter mutations [27] and alternative promoter
regions [28].
The new allele described here is unusual in several
respects. The O1v-characteristic mutations, 106C>T,
188G>A and 220C>T in exons 3, 4 and 5, respectively, in
combination with the common A2-specific sequence in
exon 7 suggested that the allele is an O1v-A2 [O02-A201]
hybrid having a crossing-over point after nt. 220 in exon
5 and before nt. 261 in exon 6. A deletion at nt. 261 is the
most common inactivating event creating O alleles and is
present in both O1 and O1v alleles and hybrid variants of
these as shown in Figure 3. This mutation is absent from
the five hybrid alleles described here and hence the cross-
over should occur upstream of this position. In an attempt
to determine the cross-over point more precisely and con-
firm the identity of the two contributing alleles we
sequenced the intervening intron (intron 5) in the hope
that allele-specific mutations were present in this intron,
by analogy with our previous findings in intron 6 [9]. As
Table 1 shows, eight of the 554 nucleotides in the intron
were polymorphic. In this intron the A1, A2, B and O1 alle-
les are very similar, differing only at nt. 336 in the O1 allele
and at nt. 529 in only one of the three B alleles tested.
More pronounced differences were observed in the O2
alleles that differed at each of the first three polymorphic
positions (the complex variations in the O2 allele will be
presented elsewhere), and in the O1v alleles, that differed
at four of these sites. This latter information allowed us to
determine the crossing-over point to occur in intron 5
between nt. 103 and 306, and that the allele is indeed an
O1v-A2 hybrid (Figure 2).
This new allele showed some additional interesting char-
acteristics. The mutation, nt. 46G>A (Ala16Thr) in exon 2,
has not been described in any other context, nor could we
detect this mutation when we analysed 260 alleles from
individuals of diverse ethnic background (of whom about
40 were African). Its occurrence in all five index samples,
albeit from individuals of Black African descent, collected
from diverse parts of the world is surprising.
Few mutations have been found in exon 4. Both 188G>A
and 189C>T have hitherto been exclusive characteristics
of the O1v allele; 190 G>A has only been found in some
Brazilian Black O1 alleles [29]; and 203G>C occurred in
some Scandinavian Aweak  alleles [16]. The finding of
188G>A without 189C>T in the new allele was also unex-
pected. When we screened more than 200 alleles at these
positions we found one otherwise normal O1v allele (Afri-
can) having 188G>A but lacking 189C>T and one
otherwise normal O1 allele (Jordanian) having 188G>A.
Although infrequent, additional genetic diversity obvi-
ously exists in individuals with common ABO
phenotypes.
Several hybrid alleles at the ABO locus have been reported
previously (reviewed in [17] and summarised in Figure 3).
About half of these alleles are O alleles containing the
common inactivating deletion at nt. 261 contributed by
Representation of the exons and introns in A2 and O1v alleles  and the new hybrid allele Figure 2
Representation of the exons and introns in A2 and O1v alleles 
and the new hybrid allele. Exons are represented as thick 
boxes and introns as thin boxes. They are drawn approxi-
mately to scale except for the approx 13 kbp long intron 1. 
Filled regions indicate an A2 sequence and unfilled regions an 
O1v sequence. The hatched region in the hybrid allele indi-
cates the cross-over region. The grey area is presumed to 
have an O1v allele sequence, but lack of known mutations in 
exons 1 and 2 and the unsequenced intron 1 does not allow 
proof of this. The asterisks indicate the localisation of the 
four missense mutations compared to the common A2 allele.
O1v
A2
Novel
O1v-A2 
hybrid
Phenotype
A2
O
Aweak
* ***
Hybrid        formation
AlleleBMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/17
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the O1 or O1v part of the hybrid. The others described so
far are A alleles of varying activity, containing initial A or
B sequences followed by O1 or O1v sequences, where the
critical nt. 261 is supplied by the A or B allele and is thus
not deleted. The decreased A antigen expression is attrib-
uted to mutations in exon 7 (which encodes the enzyme's
active site) contributed by the O1v allele. This novel Aweak
allele described here is the first example of a "reverse"
hybrid, where the weakening of enzyme activity from A2
to Aweak  may be due to the concerted effect of the
mutations in exon 2 at 46G>A (Ala16Thr), exon 3 at
106G>T (Val36Phe), exon 4 at 188G>A (Arg63His) and
exon 5 at 220C>T (Pro74Ser). However, theoretically the
Aweak phenotype may depend on only one or a combina-
tion of some of these four mutations.
Based on the linear structure, the former two substitutions
presumably occur in or near the predicted transmembrane
domain whilst the latter two localise to the postulated
stem region of the Golgi-membrane-anchored enzyme.
None of them is thought to occur in the proximity of the
active site, which would be expected to have the normal
A2 enzyme structure based on the sequence of exon 7. In
order to visualize this prediction, we created a three-
dimensional computer model of the A transferase for
mapping of two of the mutated amino acid positions onto
the crystal-structure-based molecular surface. The result
appears to confirm that residues 63 and 74 are localised
far from the enzymatically active site in a stalk-like part of
the protein (Figure 1). It should be emphasized that we
did not attempt to determine the effect that these muta-
tions would have on enzymatic function or fine structure
of the gene product. Expression studies beyond the scope
of this study or the future finding of other samples
carrying other combinations of the above mutations may
be able to address this issue.
The mutations found early on in intron 3 of this new
hybrid allele (the consensus 205C rather than the O1v-spe-
cific 205C>T, as well as the unique 354G>A and 399G>A)
Known hybrid alleles at the ABO locus Figure 3
Known hybrid alleles at the ABO locus. The common alleles are also shown for comparison. Only changes from the consensus 
(A1-1) sequence are shown. Mutations causing amino acid changes are shown in bold face. The yellow areas indicate a reading 
frame shift. The blue areas indicate untranslated regions. The introns are represented by the thick, dark vertical bars. The blue 
rectangles indicate the region of the allele where a crossing over event occurred. ?, indicates that the nucleotide at this position 
was not described.
Exon 1 2 3 4 5 6 7
nt. position 46 106 188 189 220 261 297 352 467 498 526 564 595 641 646 657 681 703 721 729 771 796 803 829 930 1061 1062 1096 1126 Reference
Allele * Database
A
1
-1 A101 G G GC C G A CCCCCTTCGGCCCCGGG C G 2
A
2
-1 A201 T  -4
B-1 B101 G G T AA C AA 2
O
1-1 O01  - 2
O
1v-1 O02 TA T T - G A A T A 2, 6, 7
new hybrid ATA T T  -
A
1
-5 [B-O
1] (A104) G ?8
A
1
-6 [B-O
1v] A204 G G T A T A ?8
A
x
-2 [A-O
1v] Ax03 A AT A 9
A
x
-3 [B-O
1v] Ax02 G A AT A 9
A
x
-4 [A-O
1v] Ax05 A AT A 16
A
x
-5 [A-O
1v] Ax06 A AT A 16
A
el
-2 [A-O
1v-A
1] Ael02 TA A? 1 5
O
R-1  [O
1v-B] O24 TA T T - GGT A A C A A 2 9
O
R-2  [O
1-O
1v]  - GA A T A 2 9
O
R-3  [O
1-O
1v] T - GA A T A 2 9
O
R-4  [O
1-O
1v] ?? ? ?- AA T A ? 8
O
R-5 [O
1-O
1v-O
1] A T  - 29
O
R-6  [O
1-A
2] O22  - T  - 29, 32
O
R-7  [O
1v-A
1] ?? ? ?- G ?8
O
R-8  [A-O
1v] O19 A AT A 37
O
R
-9 [B-O
1v] G A AT A 37
O
R
-10 [B-O
1v] O20 G A AT A 37
O
R
-11 [A-O
1v-A
1] TA A? 3 7
O
R
-12 [O
1-O
1v] O18 ? ?? ?- AA T A ? 3 7
O
R
-13 [O
1v-O
1/A
1] O05/O17 ?? ? ? - G ? 37, 38
O
R-14  [O
1v-B] ?? ? ? - GGT A A C A A 3 9
Amino acid 16 36 63 63 74 87 99 118 156 166 176 188 199 214 216 219 227 235 241 243 257 266 268 277 310 354 354 375
Consensus Ala Val Arg Arg Pro Val Thr Pro Thr Arg Arg Arg Met Phe His Pro Gly Arg Ala Pro Leu Gly Val Leu Pro Pro
Change Thr Phe His Ser Leu Gly Arg Ile Ser Trp Met Ala MetBMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/17
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appear to be a specific characteristic of this new allele
since intron 3 of the three control O1v alleles from Black
African individuals did not differ from Caucasian sam-
ples. On the other hand, the four new mutations found in
intron 6 of the new hybrid allele were also found in the
three Black African A2 alleles, which led us to conclude
that the alterations observed in intron 6 may simply
reflect a common ancestral A2 allele of African evolution-
ary lineage.
The A and B glycosyltransferases compete for the same
acceptor glycoconjugates. However, the weaker A activity
due to this new allele was also observed serologically,
although to a lesser degree, in the mother of one of these
AweakB individuals who had inherited the hybrid allele in
combination with an O allele and hence lacked a B gene.
This may indeed be the reason why all five index samples
studied here were AweakB. Obviously, the weakening effect
of this hybrid is relatively mild so that the Aweak pheno-
type, produced when the A hybrid glycosyltransferase is
allowed to convert the available acceptor glycoconjugates
to A without any competition from a B transferase, will
sometimes escape detection in routine laboratories, espe-
cially if automated blood grouping equipment is used.
Conclusions
A new hybrid, Aweak allele with O1v and A2 characteristics
with a crossing over point in intron 5 has been found at
the blood group ABO locus in five individuals of diverse
Black African backgrounds. To our knowledge this is the
only defined ABO subgroup allele so far associated with
an African ethnic origin.
Sequencing of all seven exons of these Aweak alleles showed
two major exons (exons 6 and 7) were identical to the
most frequent A2 allele, although the intervening intron 6
had mutations only found so far in Black Africans. Exons
1–5 had sequences consistent with the O1v allele, except
for two novel changes, the most important one of which
(46G>A) results in an amino acid substitution in the puta-
tive trans-membrane region of the translated protein (gly-
cosyltransferase). The other novel change (lack of
189C>T) led further to the identification of two new O
alleles.
This new hybrid allele shows how mutations in early
exons, far from the enzyme product's active site, can affect
expression of the blood group A antigen on the erythro-
cyte surface.
Methods
Blood samples and blood group serology
Blood samples from individuals living in Portugal, Swe-
den, Switzerland and the USA were referred to our labora-
tory for genomic analysis due to unclear phenotyping.
Blood samples from first-degree relatives were only
obtained in one case.
One hundred and thirty blood samples available at the
Blood Centre, University Hospital, Lund from blood
donors and other apparently healthy individuals with
mixed phenotypes and mixed ethnicity (Africans, Europe-
ans, Jordanians) were used for screening purposes. Their
ABO group was determined according to current practice
[30].
Routine ABO genotyping
All oligonucleotide primers used were synthesized by
DNA Technology ApS (Aarhus, Denmark). DNA was pre-
pared in Lund using a simple salting-out method [31].
The initial ABO genotyping comprised duplex PCR-RFLP
and PCR-ASP analysis of exons 6 and 7 across intron 6 and
subsequently DNA sequencing of the ABO gene and its
regulatory elements was performed [7,16,19,20].
Selected homozygous and heterozygous DNA (samples
homozygous for O2 and B allele were not available) from
blood donors and other apparently healthy individuals at
the reference laboratory in Lund was used for identifica-
tion of introns 2 to 5 from the common alleles A1, A2, B,
O1, O1v and O2.
PCR amplification of the ABO gene for DNA sequencing
Primers used to amplify DNA fragments and for allele-
specific direct sequencing of the seven exons and intron 6
are described elsewhere [16].
Alternatively, polymerase chain reaction (PCR) was car-
ried out using Expand High Fidelity PCR system (Roche
Molecular Systems, Pleasanton, CA, USA) to amplify dif-
ferent intron fragments and for screening for mutations
188G>A and 46A>G. Amplifications were performed with
primer pairs as shown in Table 2. An internal positive con-
trol primer pair was used in each PCR reaction. Amplifica-
tion was performed in a reaction volume of 20 µl with 0.5
µmol/L of each primer, 2 nmol of each dNTP, and 100 ng
of genomic DNA. As thermostable enzyme we used 0,5U
from the Expand High Fidelity PCR System in the sup-
plied buffer 2 with a final Mg2+ concentration of 1.5 mM
according to the manufacturer (Roche Molecular Sys-
tems). After an initial denaturation step at 95°C for 2 min
followed 10 cycles of denaturation (94°C for 20 s),
annealing (65°C for 45 s) and extension (72°C for 1.5
min), then 25 cycles at 94°C for 20 s, 61°C for 30 s and
72°C for 1 min and a final extension for 5 min.
PCR products were excised from 3% agarose gels (Seakem,
FMC Bioproducts, Rockland, ME, USA) stained with
ethidium bromide (0.56 mg/l gel, Sigma Chemicals, St.BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/17
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Louis, MO, USA) following high-voltage electrophoresis
and purified using the Qiaquick gel extraction kit (Qiagen
GmbH, Hilden, Germany).
The Big Dye Terminator Cycle Sequencing kit (Applied
Biosystems, Foster City, CA, USA) and an ABI PRISM 310
Genetic Analyser (Applied Biosystems) were used for
direct DNA sequencing with capillary electrophoresis and
automated fluorescence-based detection according to the
manufacturer's instructions. Sequence analysis was per-
formed with SeqEd software 1.03 (Applied Biosystems).
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Note
1Nomenclature used in the Blood Group Antigen Gene
Mutation Database http://www.bioc.aecom.yu.edu/
bgmut/abo.htm.
Table 2: Oligonucleotide primers used for PCR amplification, sequencing and screening in this study.
Primer name F/R* Nucleotide sequence (5' → 3') Position Function
mo-21s F1–3 GGTGAGAGAAGGAGGGTGAG intron 1 amplification-sequencing of intron 2 for all alleles
mo-31r R1,4 CCAGCACCCCGGCCAGCA intron 3 amplification-sequencing of intron 2 /screening of 
46G>A
ABO-46A-F F4 CCAGGAAAACCAAAATGCCACA exon 2 screening of 46G>A
ABO-106G-R R2 TAGACTTCTGGGGCTTAGGAC exon 3 amplification of O2 allele in intron 2
ABO-106T-R R3 AGACTTCTGGGGCTTAGGAAC exon 3 amplification of new hybrid allele in intron 2
ABO-inII-123F F GTTATCAGGGTCCTAAGGACAG intron 2 sequencing of intron 2
ABO-inII-660R R CTGCCTGTTGGTCCCTTCCTC intron 2 sequencing of intron 2
ABO-133s F5–8 GCCCCAGAAGTCTAATGCCAG exon 3 amplification-sequencing of introns 3 and 4
ABO-202 cons-R R5 GGGAGGCACTGACATTATACC intron 4/exon 4 amplification-sequencing of intron 3 (except O2, B 
and hybrid alleles**)
ABO-188A-R R6,9 ATACCTTGGCAACGAGACGT intron 4/exon 4 amplification-sequencing of hybrid allele in intron 
3 and screening
ABO-220 T-R R7,10 CCACGGTGTCAGCACCTTTGA exon 5 amplification-sequencing of O2 allele in introns 3 
and 4
ABO-220 C-R R8,11 CACGGTGTCAGCACCTTTGG exon 5 amplification-sequencing of B allele in introns 3 
and 4
ABO-inIII-F F9 GCTGGCCGTTACAGGGTCTG intron 3 screening of 188G>A mutation in exon 4
ABO-inIII-425F F GCTGCCCTCATCTCTGTGACA intron 3 sequencing of intron 3
ABO-inIII-672F F GTGCTATGGCCTCTGTTGGG intron 3 sequencing of intron 3
ABO-inIII 916F F CTCTGGCAGTTGATGCTGGC intron 3 sequencing of intron 3
mo-41s F10,11 TAAATCCTGCTCCTAGACTAAAC intron 3 amplification-sequencing of intron 4
ABO-inIV 170F F GACTTGGCCCTCGTCCTGCA intron 4 sequencing of intron 4
ABO-inIV-429R R GACTAGCCTGGCCAACATGG intron 4 sequencing of intron 4
ABO-inIV-852F F TAGCAACTCCATTTTCCCTCCC intron 4 sequencing of intron 4
ABO-inIV 877R R GTTGGAGTAGCAGACTCATAACA intron 4 sequencing of intron 4
ABO-inIV 1122F F CTCCTGAGCCTCTACAATCCT intron 4 sequencing of intron 4
ABO-inIV 1411F F CTCTACGTCCCTCCCAGCCT intron 4 sequencing of intron 4
ABO-229F F12,13 CTACCCCCAGCCAAAGGTGC exon 5 amplification-sequencing of all alleles in intron 5
ABO-297A-R R12 GTTGAGGATGTCGATGTTGAAT exon 6 amplification-sequencing of A1, A2, O1 and hybrid 
allele in intron 5
ABO-297G-R R13 GTTGAGGATGTCGATGTTGAAC exon 6 amplification-sequencing of B, O1v and O2 alleles in 
intron 5
mo-101s F4,9 CCGTCCGCCTGCCTTGCAG intron 6 internal control primer pair in screening
EPB-79R R4,9 TACTTGTTCAGGTGGCTCTCGTC exon 7 internal control primer pair in screening
* Forward/reverse primer. ** O2, B and hybrid alleles were examined in heterozygous samples. The numeral superscripts denote primer 
combinations. Primers with the same number were used in the same primer mixes for amplification of ABO gene fragments.BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/17
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